SVB Leerink analyst Marc Goodman maintains Evolus (NASDAQ:EOLS) with a Outperform and raises the price target from $18 to $20.
Why Jaguar Health Stock Is Soaring After-Hours
Jaguar Health reported all proposals were approved by stockholders, and the company will not be implementing a reverse split at this time.